α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action - The Lancet
Respiratory Medicine Skip to Main Content Advertisement The Lancet Respiratory Medicine …

The clinical manifestations of COVID-19 are heterogeneous: 46.4% of patients admitted into
hospital reported to have at least one comorbidity. Comorbidities such as COPD, diabetes …

Alpha-1 antitrypsin deficiency (AATD) is highly prevalent in Portugal. It is estimated that 1:
5249 individuals have a ZZ genotype, and 1: 281 have a SZ genotype [1]. Patients with …

At the time when WHO reports that Italy is currently the fifth country in the world for number of
cases of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection (225 …

Background: Epidemiologic studies have reported that the geographical distribution of the
prevalence of allelic variants of serine protein inhibitor-A1 (SERPINA1) and severe cases of …

Among 68 countries in the world, severity of the COVID-19 epidemic was correlated with the
prevalence of α-1 antitrypsin (AAT) deficiency. For the severe variant, PI* Z, the correlation …

Coronavirus disease (COVID-19) is a novel illness and is a rapidly evolving pandemic with
unprecedented impact on global health in the last 100 years (1). At the time of submission of …

Many drugs have been approved for clinical trials for the treatment of COVID-19 disease,
focusing on either antiviral or anti-inflammatory approaches. Combining antiviral and anti …

Alpha 1 Antitrypsin deficiency (AATD) is a hereditary condition characterized by low serum
Alpha 1 Antitrypsin (AAT) levels and a predisposition towards early-onset emphysema …

Infection rates, severity, and fatalities due to COVID‐19, the pandemic mediated by SARS‐
CoV‐2, vary greatly between countries. With few exceptions, these are lower in East and …